% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Seller:285049,
author = {A. Seller$^*$ and C. Hackenbruch$^*$ and J. Walz$^*$ and A.
Nelde and J. Heitmann$^*$},
title = {{L}ong-{T}erm {F}ollow-{U}p of {COVID}-19
{C}onvalescents-{I}mmune {R}esponse {A}ssociated with
{R}einfection {R}ate and {S}ymptoms.},
journal = {Viruses},
volume = {15},
number = {10},
issn = {1999-4915},
address = {Basel},
publisher = {MDPI},
reportid = {DKFZ-2023-02192},
pages = {2100},
year = {2023},
abstract = {SARS-CoV-2 has spread worldwide, causing millions of deaths
and leaving a significant proportion of people with
long-term sequelae of COVID-19 ('post-COVID syndrome').
Whereas the precise mechanism of post-COVID syndrome is
still unknown, the immune response after the first infection
may play a role. Here, we performed a long-term follow-up
analysis of 110 COVID-19 convalescents, analyzing the first
SARS-CoV-2-directed immune response, vaccination status,
long-term symptoms (approximately 2.5 years after first
infection), and reinfections. A total of $96\%$ of
convalescents were vaccinated at least once against
SARS-CoV-2 after their first infection. A reinfection rate
of $47\%$ was observed, and lower levels of anti-spike IgG
antibodies after the first infection were shown to associate
with reinfection. While T-cell responses could not be
clearly associated with persistent postinfectious symptoms,
convalescents with long-term symptoms showed elevated
SARS-CoV-2-specific antibody levels at the first infection.
Evaluating the immune response after the first infection
might be a useful tool for identifying individuals with
increased risk for re-infections and long-term symptoms.},
keywords = {Humans / COVID-19 / Reinfection / SARS-CoV-2 / Follow-Up
Studies / Antibodies, Viral / COVID-19 (Other) / SARS-CoV-2
(Other) / immune response (Other) / post-COVID syndrome
(Other) / Antibodies, Viral (NLM Chemicals)},
cin = {TU01},
ddc = {050},
cid = {I:(DE-He78)TU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37896879},
pmc = {pmc:PMC10611319},
doi = {10.3390/v15102100},
url = {https://inrepo02.dkfz.de/record/285049},
}